Company intelligence / Profile preview

pharma&

Ownership: Private
Development stage: Commercial

Overview

pharma& has acquired and integrated 10+ medicines over the past five years, with a portfolio that includes treatments for psychiatric disorders, hematology, oncology, and other conditions[2]

Therapeutic areas: OncologyImmunologyHematologyPsychiatryGastroenterology
Modalities: Small moleculesbiologics
Industry: Biotech

Drug pipeline

5 assets

rucaparib

Commercial

Indications: metastatic castration-resistant prostate cancer, advanced ovarian cancer

4 more assets in the full pipeline.

Request access →

Partnerships

Joint venture with Heritage Biologics LLC and Summit SD LLC

Beyond the preview

Go deeper on pharma&.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pharma&.

Explore the full profile